Revlon raises capital
This article was originally published in The Rose Sheet
Executive Summary
Cosmetics firm issues $363 mil. in 12% senior secured notes due 2005, Revlon announces. Notes were sold at 96.6% of principal value and proceeds were paid into escrow pending completion of a new credit agreement. Company entered new credit agreement with bank consortium Nov. 30, providing $250 mil. in credit facilities. Net proceeds from offering and credit facility will be used to repay debt, Revlon notes...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.